Elanco Animal Health Incorporated

What they do

Elanco operates as a single segment in the animal health industry, selling products for dogs, cats, cattle, poultry, swine and sheep. The portfolio includes parasiticides, dermatology, vaccines, pain products and farm animal feed ingredients, marketed under approximately 200 brands. Products are sold worldwide to distributors, independent retailers, veterinarians and farm animal producers, with an omnichannel presence including e-commerce.

Revenue drivers

• Pet Health — In Q2 2026, Pet Health revenue was $718 million, up 12% year-over-year (11% organic constant currency), led by U.S. Pet Health growth of 11% and new products like Zenrelia and Credelio Quattro.
• Farm Animal — Q2 2026 Farm Animal revenue was $633 million, up 9% year-over-year (5% organic constant currency), with cattle up 12% and poultry up 4%, driven by innovation and the AHV International acquisition.
• U.S. market — The U.S. is the largest market, accounting for 47% of total revenue in 2025. U.S. Pet Health and U.S. Farm Animal each grew 11% in Q2 2026.

Recent performance

For Q2 2026, Elanco reported revenue of $1,368 million, up 10% year-over-year (8% organic constant currency). Reported net income was $54 million, adjusted net income $174 million, and adjusted EPS $0.34, up 31% year-over-year. Adjusted EBITDA was $288 million, a 21% increase, with adjusted EBITDA margin of 21.2%. Net leverage was 3.1x adjusted EBITDA, and the company raised its full-year 2026 outlook.

Strategy

Elanco's strategy is centered on Innovation, Portfolio and Productivity (IPP). The company is investing in late-stage potential blockbusters (e.g., Zenrelia, Credelio Quattro, Befrena) and expanding into international markets. In December 2025, it authorized a restructuring plan to close R&D facilities in Monheim (Germany) and a manufacturing site in Kansas City, exit certain farm animal implant products, and reduce headcount by about 300 employees, while expanding R&D in Indianapolis and moving some roles to lower-cost geographies. Management expects the plan to generate savings of approximately $25 million in 2026 and $60 million in 2027.

Risks

• Restructuring execution — The 2025 Restructuring Plan involves facility closures and headcount reductions that could disrupt operations or fail to achieve expected savings.
• Competition in pet health — Pet health markets, especially JAK inhibitors and parasiticides, are competitive; Zenrelia and Credelio Quattro face rivals and may not sustain market share.
• Regulatory approvals — Several products (e.g., Credelio Quattro, Befrena) rely on regulatory approvals in multiple jurisdictions; delays or denials could limit revenue growth.
• Debt and leverage — While net leverage is improving, long-term debt stood at $3.66 billion as of June 30, 2026, and high debt could constrain financial flexibility.

Outlook

Management raised full-year 2026 guidance: revenue of $5.09–5.14 billion (6–7% organic constant currency growth), adjusted EBITDA of $1.01–1.035 billion (13% growth at midpoint), adjusted EPS of $1.10–1.16 (20% growth at midpoint), and innovation revenue target of $1.25 billion. They also improved the year-end net leverage ratio target to approximately 3.0x adjusted EBITDA. The company expects sustainable mid-single-digit CAGR in animal health, driven by pet and protein demand.